Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
| Current Price | ₹363.95 |
|---|---|
| Market Cap | ₹3,408 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 32.6 |
| Return on Equity | 14.31% |
| 52-Week Range | ₹207.70 – ₹447.80 |
| Beta (1Y) | 0.99 |
| Dividend Yield | 0.11% |
1. Pharmaceutical Products Including Ingredients and Intermediaries-100%
SMS Pharmaceuticals Ltd is trading at ₹363.95, with a market capitalisation of ₹3,408 Cr.
SMS Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
SMS Pharmaceuticals Ltd has a P/E of 32.6 and a return on equity of 14.31%.